Consideration for Coronavirus Disease 2019 Drug Treatment in Patients with Epilepsy on Antiepileptic Drugs
- Author:
Jung-Ick BYUN
1
;
Jun-Sang SUNWOO
;
Kyung Wook KANG
;
Keun Tae KIM
;
Daeyoung KIM
;
Dong Wook KIM
;
Saeyoon KIM
;
Se Hee KIM
;
Woojun KIM
;
Hye-Jin MOON
;
Hea Ree PARK
;
Jong-Geun SEO
;
Min Kyung CHU
;
Kyoung Jin HWANG
;
Dae-Won SEO
;
Author Information
- Publication Type:Review Article
- From:Journal of the Korean Neurological Association 2022;40(2):121-126
- CountryRepublic of Korea
- Language:Korean
- Abstract: Several medications are approved to treat coronavirus disease 2019 (COVID-19) in Korea including nirmatrelvir/ritonavir, remdesivir, and regdanvimab. There is potential drug-drug interaction between antiepileptic drugs (AEDs) and the medications used to treat COVID-19. Several AEDs such as phenytoin, carbamazepine, phenobarbital, and primidone are strong cytochrome P450 inducers and can inhibit the drugs used for COVID-19. Particularly, these drugs are contraindicated with nirmatrelvir/ritonavir (Paxlovid®). There is a weaker drug-drug interaction between the AEDs and remdesivir. No significant interaction has been reported between the AEDs and molnupiravir. Pharmacokinetic interactions of the AEDs are important in effective management of COVID-19 in patients with epilepsy.
